PMID- 26755507
OWN - NLM
STAT- MEDLINE
DCOM- 20160629
LR  - 20220311
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 34
IP  - 7
DP  - 2016 Mar 1
TI  - Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian 
      Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude 
      des Cancers de l'Ovaire Study.
PG  - 706-13
LID - 10.1200/JCO.2015.62.1474 [doi]
AB  - PURPOSE: Volasertib is a potent and selective cell-cycle kinase inhibitor that 
      induces mitotic arrest and apoptosis by targeting Polo-like kinase. This phase II 
      trial evaluated volasertib or single-agent chemotherapy in patients with 
      platinum-resistant or -refractory ovarian cancer who experienced failure after 
      treatment with two or three therapy lines. PATIENTS AND METHODS: Patients were 
      randomly assigned to receive either volasertib 300 mg by intravenous infusion 
      every 3 weeks or an investigator's choice of single-agent, nonplatinum, cytotoxic 
      chemotherapy. The primary end point was 24-week disease control rate. Secondary 
      end points included best overall response, progression-free survival (PFS), 
      safety, quality of life, and exploratory biomarker analyses. RESULTS: Of the 109 
      patients receiving treatment, 54 received volasertib and 55 received 
      chemotherapy; demographics were well balanced. The 24-week disease control rates 
      for volasertib and chemotherapy were 30.6% (95% CI, 18.0% to 43.2%) and 43.1% 
      (95% CI, 29.6% to 56.7%), respectively, with partial responses in seven (13.0%) 
      and eight (14.5%) patients, respectively. Median PFS was 13.1 weeks and 20.6 
      weeks for volasertib and chemotherapy (hazard ratio, 1.01; 95% CI, 0.66 to 1.53). 
      Six patients (11%) receiving volasertib achieved PFS fore more than 1 year, 
      whereas no patient receiving chemotherapy achieved PFS greater than 1 year. No 
      relationship between the expression of the biomarkers tested and their response 
      was determined. Patients treated with volasertib experienced more grade 3 and 4 
      drug-related hematologic adverse events (AEs) and fewer nonhematologic AEs than 
      did patients receiving chemotherapy. Discontinuation resulting from AEs occurred 
      in seven (13.0%) and 15 (27.3%) patients in the volasertib and chemotherapy arms, 
      respectively. Both arms showed similar effects on quality of life. CONCLUSION: 
      Single-agent volasertib showed antitumor activity in patients with ovarian 
      cancer. AEs in patients receiving volasertib were mainly hematologic and 
      manageable.
CI  - (c) 2016 by American Society of Clinical Oncology.
FAU - Pujade-Lauraine, Eric
AU  - Pujade-Lauraine E
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany. 
      epujade@arcagy.org.
FAU - Selle, Frederic
AU  - Selle F
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Weber, Beatrice
AU  - Weber B
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Ray-Coquard, Isabelle-Laure
AU  - Ray-Coquard IL
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Vergote, Ignace
AU  - Vergote I
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Sufliarsky, Jozef
AU  - Sufliarsky J
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Del Campo, Josep Maria
AU  - Del Campo JM
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Lortholary, Alain
AU  - Lortholary A
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Lesoin, Anne
AU  - Lesoin A
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Follana, Philippe
AU  - Follana P
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Freyer, Gilles
AU  - Freyer G
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Pardo, Beatriz
AU  - Pardo B
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Vidal, Laura
AU  - Vidal L
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Tholander, Bengt
AU  - Tholander B
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Gladieff, Laurence
AU  - Gladieff L
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Sassi, Mouna
AU  - Sassi M
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Garin-Chesa, Pilar
AU  - Garin-Chesa P
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Nazabadioko, Serge
AU  - Nazabadioko S
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Marzin, Kristell
AU  - Marzin K
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Pilz, Korinna
AU  - Pilz K
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
FAU - Joly, Florence
AU  - Joly F
AD  - Eric Pujade-Lauraine, Centre des Cancers de la Femme et Recherche Clinique, 
      Paris; Frederic Selle, Hopitaux Universitaires de l'Est Parisien-site Tenon and 
      Alliance Pour la Recherche En Cancerologie, Paris; Beatrice Weber, Centre Alexis 
      Vautrin, Vandoeuvre-les-Nancy; Isabelle-Laure Ray-Coquard, Centre Leon Berard and 
      Universite Claude Bernard-Lyon I, Lyon; Alain Lortholary, Centre Catherine de 
      Sienne, Nantes; Anne Lesoin, Centre Oscar Lambret, Lille; Philippe Follana, 
      Centre Antoine-Lacassagne, Nice; Gilles Freyer, Lyon University, Hospices Civils 
      de Lyon, Pierre-Benite Cedex; Laurence Gladieff, Institut Claudius Regaud-IUCTO, 
      Toulouse; Mouna Sassi and Serge Nazabadioko, Boehringer Ingelheim, Reims; 
      Florence Joly, Centre Francois Baclesse, Caen, France; Ignace Vergote, University 
      Hospitals Leuven, KU Leuven, Leuven, Belgium; Jozef Sufliarsky, National Cancer 
      Institute, Bratislava, Slovakia; Josep Maria Del Campo, Hospital University, Vall 
      d'Hebron; Beatriz Pardo, Institut Catala d'Oncologia-Instituto de Investigacion 
      Biomedica de Bellvitge; Laura Vidal, Hospital Clinic de Barcelona, Barcelona, 
      Spain; Bengt Tholander, Uppsala University Hospital, Uppsala, Sweden; Pilar 
      Garin-Chesa, Boehringer Ingelheim, Vienna, Austria; Kristell Marzin, Boehringer 
      Ingelheim, Biberach; and Korinna Pilz, Boehringer Ingelheim, Ingelheim, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT01121406
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160111
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antineoplastic Agents)
RN  - 0 (BI 6727)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Pteridines)
RN  - BG3F62OND5 (Carboplatin)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biomarkers, Tumor/analysis
MH  - Carboplatin/therapeutic use
MH  - Cisplatin/therapeutic use
MH  - Disease Progression
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Middle Aged
MH  - Ovarian Neoplasms/*drug therapy
MH  - Pteridines/administration & dosage/*therapeutic use
MH  - Quality of Life
MH  - Treatment Outcome
EDAT- 2016/01/13 06:00
MHDA- 2016/06/30 06:00
CRDT- 2016/01/13 06:00
PHST- 2016/01/13 06:00 [entrez]
PHST- 2016/01/13 06:00 [pubmed]
PHST- 2016/06/30 06:00 [medline]
AID - JCO.2015.62.1474 [pii]
AID - 10.1200/JCO.2015.62.1474 [doi]
PST - ppublish
SO  - J Clin Oncol. 2016 Mar 1;34(7):706-13. doi: 10.1200/JCO.2015.62.1474. Epub 2016 
      Jan 11.